Clinical trial
Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia…
NCT00193466 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193466 |
|---|---|
| Title | Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Official title | Phase II Trial of Rituximab/Fludarabine Followed by CAMPATH-1H in the First-Line Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkins Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, Fludarabine, CAMPTH-1H |
| Enrollment | 40 |
| Start date | Jan 1, 2002 |
| Primary completion | Jan 1, 2007 |
| Completion | Apr 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 30, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: